GRI Bio Secures $6.5M in January ATM Offering, Extends Cash Runway into Q1 2027
Summary
GRI Bio announced it raised an additional $6.5 million in January via its ATM offering, extending its cash runway into Q1 2027 and addressing prior going concern warnings.
Key Events
-
Capital Raise
GRI Bio secured an additional $6.5 million in gross proceeds through its At-The-Market (ATM) offering during January 2026.
-
Extended Cash Runway
The company now expects its existing cash and cash equivalents to fund operations into the first quarter of 2027, addressing previous liquidity concerns.
-
Financial Reiteration
The filing reiterates full-year 2025 financial results, reporting $8.2 million in cash at year-end 2025 and a net loss of $12 million for the year.
-
Clinical Data Summary
The company summarized previously announced positive Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis and progress on GRI-0803.
Analysis
This 8-K reiterates previously disclosed full-year 2025 financial results and positive Phase 2a clinical data. However, the material new information is the successful raise of an additional $6.5 million in gross proceeds through its At-The-Market (ATM) offering in January 2026. This capital infusion is critical for GRI Bio, a micro-cap company that recently disclosed a going concern warning in its 10-K filing on January 30, 2026. The company now projects its cash and cash equivalents will fund operations into the first quarter of 2027, significantly extending its financial runway and mitigating immediate liquidity concerns.
At the time of this filing, GRI was trading at $2.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $2.40 to $314.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.